Sign Out
ASTHMA RELATED DEATH: Long-acting beta2-adrenergic agonists (LABA) increase the risk of asthma-related death. Data from a large placebo controlled US study that compared the safety of another LABA (salmeterol) or placebo added to patients’ usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol is considered a class effect of LABA, including indacaterol maleate, one of the active ingredients of ULTIBRO BREEZHALER.
ULTIBRO BREEZHALER is only indicated for COPD.
The safety and efficacy of ULTIRBO BREEZHALER in patients with asthma have not been established. ULTIBRO BREEZHALER is not indicated for the treatment of asthma.
Lanjutkan dengan Google